It is no secret that medical research can provide crucial insights into disease pathology, prognostic factors, and patient outcomes. Recently, a research team from Hokkaido University in Sapporo, Japan dove…
IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…
In the past, caffeine has been somewhat of a complex or even controversial topic. While some research shares that it is bad for health, others laud caffeine’s ability to enhance…
Endometrial cancer is the most common form of cancer that develops in the uterus, and there is currently a need for more treatment options, especially when it comes to the…
According to MarketScreener, patients with endometrial cancer in Europe now have a new treatment option. Recently, the European Commission (EC) granted conditional marketing authorization to GlaxoSmithKline for their therapy JEMPERLI…
In a joint statement, biopharmaceutical companies AstraZeneca and Merck & Co., Inc. ("Merck") shared that LYNPARZA (olaparib) achieved a superiority boundary in the Phase 3 OlympiA clinical trial. During…
There are many forms of birth control available: oral contraceptives (birth control pills), intrauterine devices (IUDs), the implant or patch, condoms. But according to Cancer Therapy Advisor, a new study…
Welcome to study of the week, a new series from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
